Carregant...
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years. Although highly effective, primary and secondary nonresponse are common and associated with poor clinical outcomes and significant...
Guardat en:
| Publicat a: | Therap Adv Gastroenterol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4913332/ https://ncbi.nlm.nih.gov/pubmed/27366220 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16638833 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|